Travere Therapeutics (TVTX)
Travere Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
10.9M
Short interest
settlement 2026-10-15
5.2
Days to cover
-2.0 days vs prior
57.0%
Short share of volume
2026-11-02
144
Fails to deliver
settlement 2026-10-13
Mon 11 Jan
Next earnings
estimated date
-$80.1M
Insider flow, 90 days
0 buys, 49 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TVTX is 10,913,583 shares, down 2,042,350 shares over the last month. Over the last 48 readings it ranged from 6,971,485 shares (15 November 2024) to 15,365,503 shares (15 January 2026). At the reported average volume of 2.1M shares a day that is 5.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tvtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 10,913,583 | -13.8% | 2,082,321 | 5.24 |
| 2026-09-30 | 12,655,839 | -2.3% | 1,751,519 | 7.23 |
| 2026-09-15 | 12,955,933 | +7.9% | 1,247,781 | 10.38 |
| 2026-08-31 | 12,004,820 | +0.5% | 1,256,259 | 9.56 |
| 2026-08-14 | 11,943,638 | +2.3% | 2,095,016 | 5.70 |
| 2026-07-31 | 11,676,586 | -2.8% | 1,240,232 | 9.41 |
| 2026-07-15 | 12,015,392 | -5.3% | 1,312,513 | 9.15 |
| 2026-06-30 | 12,687,615 | -5.6% | 2,692,053 | 4.71 |
| 2026-06-15 | 13,437,418 | -4.8% | 2,103,228 | 6.39 |
| 2026-05-29 | 14,122,154 | +0.8% | 1,729,763 | 8.16 |
| 2026-05-15 | 14,008,379 | -1.5% | 3,128,402 | 4.48 |
| 2026-04-30 | 14,216,705 | +11.7% | 1,974,002 | 7.20 |
| 2026-04-15 | 12,725,544 | -5.4% | 3,410,312 | 3.73 |
| 2026-03-31 | 13,446,405 | +0.5% | 1,221,504 | 11.01 |
| 2026-03-13 | 13,383,909 | -5.6% | 1,258,175 | 10.64 |
| 2026-02-27 | 14,180,739 | -6.8% | 1,463,647 | 9.69 |
| 2026-02-13 | 15,217,326 | +5.0% | 1,413,273 | 10.77 |
| 2026-01-30 | 14,491,659 | -5.7% | 1,671,645 | 8.67 |
| 2026-01-15 | 15,365,503 | +7.3% | 4,452,964 | 3.45 |
| 2025-12-31 | 14,312,827 | +17.4% | 1,957,813 | 7.31 |
| 2025-12-15 | 12,196,281 | +11.2% | 1,513,672 | 8.06 |
| 2025-11-28 | 10,969,722 | +5.9% | 1,313,897 | 8.35 |
| 2025-11-14 | 10,355,808 | -4.8% | 2,152,492 | 4.81 |
| 2025-10-31 | 10,879,506 | -8.1% | 2,183,311 | 4.98 |
| 2025-10-15 | 11,840,340 | +5.3% | 1,631,893 | 7.26 |
| 2025-09-30 | 11,241,968 | -8.7% | 2,111,348 | 5.32 |
| 2025-09-15 | 12,319,282 | +2.0% | 3,781,660 | 3.26 |
| 2025-08-29 | 12,081,747 | -0.2% | 1,650,536 | 7.32 |
| 2025-08-15 | 12,107,746 | +14.0% | 1,713,433 | 7.07 |
| 2025-07-31 | 10,624,378 | -17.4% | 1,168,621 | 9.09 |
| 2025-07-15 | 12,859,589 | +2.9% | 1,297,625 | 9.91 |
| 2025-06-30 | 12,499,883 | +21.0% | 1,530,659 | 8.17 |
| 2025-06-13 | 10,329,311 | -17.4% | 1,586,851 | 6.51 |
| 2025-05-30 | 12,502,367 | +19.8% | 2,149,464 | 5.82 |
| 2025-05-15 | 10,434,682 | -1.9% | 1,704,041 | 6.12 |
| 2025-04-30 | 10,637,755 | -3.7% | 1,401,750 | 7.59 |
| 2025-04-15 | 11,046,107 | -4.4% | 2,146,190 | 5.15 |
| 2025-03-31 | 11,556,812 | +3.2% | 1,632,731 | 7.08 |
| 2025-03-14 | 11,194,840 | +2.3% | 1,567,861 | 7.14 |
| 2025-02-28 | 10,948,550 | -3.1% | 1,782,562 | 6.14 |
| 2025-02-14 | 11,301,636 | +18.3% | 2,269,818 | 4.98 |
| 2025-01-31 | 9,555,755 | -0.2% | 1,277,344 | 7.48 |
| 2025-01-15 | 9,577,154 | +9.8% | 1,215,520 | 7.88 |
| 2024-12-31 | 8,719,387 | +17.7% | 1,356,793 | 6.43 |
| 2024-12-13 | 7,405,769 | -2.2% | 1,061,515 | 6.98 |
| 2024-11-29 | 7,574,947 | +8.7% | 1,178,702 | 6.43 |
| 2024-11-15 | 6,971,485 | -12.8% | 1,545,857 | 4.51 |
| 2024-10-31 | 7,991,229 | -1.4% | 1,148,956 | 6.96 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of TVTX volume is 57.0%, up 29.1 points over the last five sessions. Over the last 30 readings it ranged from 27.9% (26 October 2026) to 84.1% (30 September 2026). The latest reading is in line with the 30-session average of 58.9%, on 1.2M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 690K | 1.2M | 57.0% | 0 |
| 2026-10-30 | 250K | 406K | 61.6% | 0 |
| 2026-10-29 | 326K | 562K | 58.1% | 4,511 |
| 2026-10-28 | 257K | 576K | 44.7% | 0 |
| 2026-10-27 | 266K | 652K | 40.9% | 0 |
| 2026-10-26 | 293K | 1.0M | 27.9% | 0 |
| 2026-10-23 | 293K | 558K | 52.4% | 0 |
| 2026-10-22 | 163K | 301K | 54.2% | 0 |
| 2026-10-21 | 382K | 626K | 61.0% | 400 |
| 2026-10-20 | 436K | 581K | 74.9% | 0 |
| 2026-10-19 | 206K | 549K | 37.5% | 4 |
| 2026-10-16 | 327K | 650K | 50.2% | 0 |
| 2026-10-15 | 485K | 654K | 74.2% | 4,800 |
| 2026-10-14 | 334K | 523K | 63.8% | 18 |
| 2026-10-13 | 514K | 731K | 70.4% | 1,207 |
| 2026-10-12 | 253K | 368K | 68.7% | 0 |
| 2026-10-09 | 246K | 408K | 60.4% | 0 |
| 2026-10-08 | 274K | 599K | 45.8% | 0 |
| 2026-10-07 | 472K | 891K | 52.9% | 0 |
| 2026-10-06 | 523K | 793K | 66.0% | 255 |
| 2026-10-05 | 329K | 565K | 58.2% | 136 |
| 2026-10-02 | 348K | 508K | 68.5% | 0 |
| 2026-10-01 | 512K | 713K | 71.7% | 800 |
| 2026-09-30 | 533K | 633K | 84.1% | 2 |
| 2026-09-29 | 447K | 608K | 73.4% | 0 |
| 2026-09-28 | 316K | 486K | 65.0% | 0 |
| 2026-09-25 | 270K | 417K | 64.7% | 0 |
| 2026-09-24 | 258K | 718K | 36.0% | 66 |
| 2026-09-23 | 343K | 543K | 63.2% | 0 |
| 2026-09-22 | 641K | 1.1M | 60.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in TVTX is 144 shares, up 143 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (5 October 2026) to 455,906 shares (17 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 144 | $52.02 | $7K |
| 2026-10-05 | 1 | $56.93 | $57 |
| 2026-09-17 | 455,906 | $63.48 | $28.9M |
| 2026-09-11 | 5,433 | $67.51 | $367K |
| 2026-09-04 | 10,361 | $66.54 | $689K |
| 2026-09-01 | 6,720 | $66.28 | $445K |
| 2026-08-24 | 31,117 | $65.71 | $2.0M |
| 2026-08-20 | 339 | $65.96 | $22K |
| 2026-08-19 | 8 | $63.90 | $511 |
| 2026-08-14 | 78,400 | $61.43 | $4.8M |
| 2026-08-12 | 6,206 | $60.21 | $374K |
| 2026-08-04 | 150 | $54.98 | $8K |
| 2026-07-30 | 604 | $55.56 | $34K |
| 2026-07-17 | 54 | $55.28 | $3K |
| 2026-07-16 | 1,222 | $56.74 | $69K |
| 2026-07-07 | 63,225 | $57.48 | $3.6M |
| 2026-07-02 | 1,923 | $56.34 | $108K |
| 2026-07-01 | 140 | $56.81 | $8K |
| 2026-06-30 | 89,520 | $58.30 | $5.2M |
| 2026-06-29 | 31,945 | $58.85 | $1.9M |
| 2026-06-26 | 23 | $59.03 | $1K |
| 2026-06-23 | 17 | $55.11 | $937 |
| 2026-06-22 | 200 | $55.15 | $11K |
| 2026-06-15 | 672 | $52.04 | $35K |
| 2026-06-09 | 14,263 | $47.08 | $672K |
| 2026-06-08 | 40,947 | $45.81 | $1.9M |
| 2026-06-05 | 933 | $46.18 | $43K |
| 2026-05-29 | 2,989 | $47.76 | $143K |
| 2026-05-19 | 91 | $42.89 | $4K |
| 2026-04-28 | 621 | $40.81 | $25K |
Insider trades
SEC Form 4, newest first. JSONInsiders at TVTX reported 49 open-market sells worth $80.1M in the last 90 days and no open-market buys. Latest filing: Dube Eric M (CHIEF EXECUTIVE OFFICER) on 2026-10-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 78K | $55.02 | $4.3M | 433K |
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 37K | $54.20 | $2.0M | 511K |
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 128K | $52.97 | $6.8M | 549K |
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 200K | $8.93 | $1.8M | 677K |
| 2026-10-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 44K | $26.88 | $1.2M | 477K |
| 2026-09-17 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 7K | $64.95 | $442K | 433K |
| 2026-09-17 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 102K | $64.59 | $6.6M | 440K |
| 2026-09-17 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 108K | $23.34 | $2.5M | 541K |
| 2026-09-17 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 8K | $65.07 | $539K | 117K |
| 2026-09-17 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 8K | $22.40 | $186K | 125K |
| 2026-09-16 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 96K | $63.64 | $6.1M | 433K |
| 2026-09-16 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 100K | $63.26 | $6.3M | 529K |
| 2026-09-16 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 196K | $23.34 | $4.6M | 629K |
| 2026-09-16 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 79K | $63.65 | $5.0M | 117K |
| 2026-09-16 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 94K | $63.25 | $5.9M | 196K |
| 2026-09-16 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 18K | $26.88 | $476K | 290K |
| 2026-09-16 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 55K | $15.46 | $850K | 272K |
| 2026-09-16 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 100K | $11.25 | $1.1M | 217K |
| 2026-09-16 | ROTE WILLIAM E. | Chief Research Officer | Sell | 48K | $63.61 | $3.0M | 98K |
| 2026-09-16 | ROTE WILLIAM E. | Chief Research Officer | Sell | 65K | $63.12 | $4.1M | 146K |
| 2026-09-16 | ROTE WILLIAM E. | Chief Research Officer | Exercise or conversion | 58K | $26.88 | $1.5M | 211K |
| 2026-09-16 | ROTE WILLIAM E. | Chief Research Officer | Exercise or conversion | 55K | $15.46 | $850K | 154K |
| 2026-09-16 | ROTE WILLIAM E. | Chief Research Officer | Exercise or conversion | 350 | $17.96 | $6K | 99K |
| 2026-09-15 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 400 | $65.31 | $26K | 88K |
| 2026-09-15 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 2K | $63.69 | $121K | 88K |
| 2026-09-15 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 21K | $62.61 | $1.3M | 90K |
| 2026-09-15 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 27K | $62.00 | $1.7M | 111K |
| 2026-09-15 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Exercise or conversion | 20K | $17.44 | $349K | 138K |
| 2026-09-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 270 | $65.31 | $18K | 433K |
| 2026-09-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 3K | $63.64 | $197K | 433K |
| 2026-09-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 29K | $62.66 | $1.8M | 436K |
| 2026-09-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 63K | $61.99 | $3.9M | 465K |
| 2026-09-15 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 96K | $23.34 | $2.2M | 529K |
| 2026-09-15 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 300 | $65.31 | $20K | 105K |
| 2026-09-15 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 1K | $63.69 | $89K | 106K |
| 2026-09-15 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 14K | $62.63 | $869K | 107K |
| 2026-09-15 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 22K | $62.03 | $1.4M | 121K |
| 2026-09-15 | REED ELIZABETH E | Chief Legal Officer and GC | Exercise or conversion | 38K | $15.46 | $580K | 143K |
| 2026-09-15 | Inrig Jula | EVP, Head of R&D & CMO | Sell | 400 | $65.31 | $26K | 100K |
| 2026-09-15 | Inrig Jula | EVP, Head of R&D & CMO | Sell | 2K | $63.69 | $102K | 101K |
| 2026-09-15 | Inrig Jula | EVP, Head of R&D & CMO | Sell | 17K | $62.62 | $1.1M | 102K |
| 2026-09-15 | Inrig Jula | EVP, Head of R&D & CMO | Sell | 25K | $62.02 | $1.6M | 120K |
| 2026-09-15 | Inrig Jula | EVP, Head of R&D & CMO | Exercise or conversion | 32K | $8.93 | $289K | 145K |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 1K | $65.31 | $93K | 117K |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 1K | $63.65 | $89K | 118K |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 27K | $62.59 | $1.7M | 120K |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 72K | $62.05 | $4.5M | 147K |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 37K | $8.93 | $326K | 219K |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 1K | $22.40 | $31K | 183K |
| 2026-09-15 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion | 39K | $26.88 | $1.1M | 181K |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Sell | 270 | $65.31 | $18K | 98K |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Sell | 3K | $63.65 | $191K | 98K |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Sell | 29K | $62.66 | $1.8M | 101K |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Sell | 64K | $61.99 | $4.0M | 130K |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Exercise or conversion | 40K | $17.96 | $712K | 194K |
| 2026-09-15 | ROTE WILLIAM E. | Chief Research Officer | Exercise or conversion | 39K | $25.25 | $985K | 155K |
| 2026-09-15 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 300 | $63.66 | $19K | 42K |
| 2026-09-15 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 800 | $62.85 | $50K | 43K |
| 2026-09-15 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 4K | $62.13 | $266K | 43K |
| 2026-09-15 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion | 2K | $20.46 | $33K | 48K |
| 2026-09-15 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion | 1K | $22.40 | $28K | 46K |
| 2026-09-15 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion | 3K | $27.50 | $69K | 45K |
| 2026-09-10 | Meckler Jeffrey A | Director | Exercise or conversion | 10K | $26.52 | $265K | 112K |
| 2026-09-10 | Meckler Jeffrey A | Director | Sell | 3K | $68.09 | $211K | 92K |
| 2026-09-10 | Meckler Jeffrey A | Director | Sell | 14K | $67.46 | $944K | 95K |
| 2026-09-10 | Meckler Jeffrey A | Director | Sell | 1K | $66.15 | $79K | 109K |
| 2026-09-10 | Meckler Jeffrey A | Director | Sell | 2K | $65.39 | $111K | 110K |
| 2026-09-10 | Meckler Jeffrey A | Director | Exercise or conversion | 10K | $17.44 | $174K | 102K |
| 2026-09-02 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 642 | $66.37 | $43K | 118K |
| 2026-08-18 | LYONS GARY A | Director | Sell | 900 | $63.86 | $57K | 62K |
| 2026-08-18 | LYONS GARY A | Director | Sell | 4K | $63.27 | $259K | 62K |
| 2026-08-18 | LYONS GARY A | Director | Exercise or conversion | 5K | $17.44 | $87K | 67K |
| 2026-08-17 | LYONS GARY A | Director | Sell | 500 | $64.16 | $32K | 62K |
| 2026-08-17 | LYONS GARY A | Director | Sell | 3K | $63.50 | $165K | 62K |
| 2026-08-17 | LYONS GARY A | Director | Sell | 2K | $62.53 | $119K | 65K |
| 2026-08-17 | LYONS GARY A | Director | Exercise or conversion | 5K | $17.44 | $87K | 67K |
| 2026-06-22 | Inrig Jula | CHIEF MEDICAL OFFICER | Gift | 468 | $0.00 | $0 | 113K |
| 2026-06-12 | Coughlin Timothy | Director | Sell | 10K | $50.07 | $501K | 56K |
| 2026-06-12 | Coughlin Timothy | Director | Exercise or conversion | 10K | $26.52 | $265K | 66K |
| 2026-06-12 | Baynes Roy D. | Director | Sell | 5K | $50.00 | $225K | 42K |
| 2026-06-12 | Baynes Roy D. | Director | Exercise or conversion | 5K | $21.38 | $96K | 46K |
| 2026-05-19 | Williams Brinkley Ruth | Director | Grant | 4K | $0.00 | $0 | 30K |
| 2026-05-19 | Squarer Ron | Director | Grant | 4K | $0.00 | $0 | 39K |
| 2026-05-19 | Poole Sandra | Director | Grant | 4K | $0.00 | $0 | 34K |
| 2026-05-19 | Orwin John A | Director | Grant | 4K | $0.00 | $0 | 39K |
| 2026-05-19 | Meckler Jeffrey A | Director | Grant | 4K | $0.00 | $0 | 92K |
| 2026-05-19 | LYONS GARY A | Director | Grant | 4K | $0.00 | $0 | 62K |
| 2026-05-19 | Coughlin Timothy | Director | Grant | 4K | $0.00 | $0 | 56K |
| 2026-05-19 | Bruhn Suzanne Louise | Director | Grant | 4K | $0.00 | $0 | 33K |
| 2026-05-19 | Baynes Roy D. | Director | Grant | 4K | $0.00 | $0 | 42K |
| 2026-05-15 | Coughlin Timothy | Director | Sell | 3K | $43.49 | $141K | 52K |
| 2026-05-06 | ROTE WILLIAM E. | Chief Research Officer | Sell | 3K | $43.95 | $121K | 115K |
| 2026-05-06 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 2K | $43.95 | $91K | 105K |
| 2026-05-06 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 311 | $43.95 | $14K | 113K |
| 2026-05-06 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 23K | $43.95 | $989K | 433K |
| 2026-05-06 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 310 | $43.95 | $14K | 119K |
| 2026-05-05 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 2K | $46.65 | $101K | 107K |
| 2026-05-05 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 2K | $46.65 | $101K | 114K |
| 2026-05-05 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2K | $46.65 | $101K | 141K |
| 2026-05-05 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 2K | $46.65 | $102K | 119K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for TVTX worth $95.5M at the prices reported; 16 in the last 90 days worth $81.0M. Latest: ERIC DUBE filed on 2026-10-15 to sell 243,735 shares ($13.0M) from 2026-10-15.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-15 | ERIC DUBEDirector, Officer | 244K | $13.0M | 0.259% | 2026-10-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-17 | ERIC DUBEDirector, Officer | 108K | $6.9M | 0.115% | 2026-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-17 | PETER HEERMAOfficer | 8K | $526K | 0.009% | 2026-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-16 | PETER HEERMAOfficer | 173K | $10.8M | 0.183% | 2026-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-16 | WILLIAM ROTEOfficer | 113K | $7.1M | 0.120% | 2026-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-16 | ERIC DUBEDirector, Officer | 196K | $12.2M | 0.208% | 2026-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | JULA INRIGOfficer | 45K | $2.9M | 0.047% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | WILLIAM ROTEOfficer | 96K | $6.3M | 0.102% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | PETER HEERMAOfficer | 102K | $6.7M | 0.108% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | ERIC DUBEDirector, Officer | 96K | $6.3M | 0.101% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | ELIZABETH REEDOfficer | 40K | $2.6M | 0.042% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | CHRISTOPHER CLINEOfficer | 51K | $3.3M | 0.054% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | SANDRA CALVINOfficer | 5K | $354K | 0.006% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-10 | JEFFREY MECKLERDirector | 20K | $1.3M | 0.021% | 2026-09-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-18 | GARY LYONSDirector | 5K | $318K | 0.005% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | GARY A LYONSDirector | 5K | $311K | 0.005% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-12 | Coughlin TimothyDirector | 10K | $500K | 0.011% | 2026-06-12 | Wells Fargo Clearing Services |
| 2026-06-12 | ROY BAYNESDirector | 5K | $225K | 0.005% | 2026-06-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-15 | Coughlin TimothyDirector | 3K | $141K | 0.003% | 2026-05-15 | Wells Fargo Clearing Services |
| 2026-05-06 | ROTE WILLIAM E.Officer | 3K | $121K | 0.003% | 2026-05-06 | Fidelity Brokerage Services LLC |
| 2026-05-06 | ELIZABETH REEDOfficer | 2K | $91K | 0.002% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-06 | JULA INRIGOfficer | 311 | $14K | 0.000% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-06 | Dube Eric MOfficer | 23K | $989K | 0.024% | 2026-05-06 | Fidelity Brokerage Services LLC |
| 2026-05-06 | CHRISTOPHER CLINEOfficer | 310 | $14K | 0.000% | 2026-05-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-05 | Elizabeth E. ReedOfficer | 2K | $101K | 0.002% | 2026-05-05 | Morgan Stanley Smith Barney |
| 2026-05-05 | Jula InrigOfficer | 2K | $101K | 0.002% | 2026-05-05 | Morgan Stanley Smith Barney |
| 2026-05-05 | Peter HeermaOfficer | 2K | $101K | 0.002% | 2026-05-05 | Morgan Stanley Smith Barney |
| 2026-05-05 | Christopher ClineOfficer | 2K | $102K | 0.002% | 2026-05-05 | Morgan Stanley Smith Barney |
| 2026-05-05 | ROY BAYNESDirector | 5K | $210K | 0.005% | 2026-05-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-04 | ELIZABETH REEDOfficer | 20K | $900K | 0.022% | 2026-05-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-04 | JEFFREY MECKLERDirector | 8K | $360K | 0.009% | 2026-05-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-04 | JULA INRIGOfficer | 20K | $900K | 0.022% | 2026-05-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | ROY BAYNESDirector | 10K | $431K | 0.011% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-22 | ROTE WILLIAM E.Officer | 9K | $356K | 0.010% | 2026-04-22 | Fidelity Brokerage Services LLC |
| 2026-04-15 | ELIZABETH REEDOfficer | 7K | $284K | 0.007% | 2026-04-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-15 | JULA INRIGOfficer | 1K | $43K | 0.001% | 2026-04-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-15 | Dube Eric MOfficer | 64K | $2.6M | 0.069% | 2026-04-15 | Fidelity Brokerage Services LLC |
| 2026-04-15 | CHRISTOPHER CLINEOfficer | 1K | $43K | 0.001% | 2026-04-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | ELIZABETH REEDOfficer | 38K | $1.5M | 0.041% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | Elizabeth E. ReedOfficer | 7K | $303K | 0.008% | 2026-04-14 | Morgan Stanley Smith Barney |
| 2026-04-14 | GARY A LYONSOfficer | 8K | $246K | 0.009% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | Jula InrigOfficer | 7K | $303K | 0.008% | 2026-04-14 | Morgan Stanley Smith Barney |
| 2026-04-14 | Peter HeermaOfficer | 7K | $303K | 0.008% | 2026-04-14 | Morgan Stanley Smith Barney |
| 2026-04-14 | CHRISTOPHER CLINEOfficer | 9 | $370 | 0.000% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | Christopher ClineOfficer | 7K | $304K | 0.008% | 2026-04-14 | Morgan Stanley Smith Barney |
| 2026-04-14 | SANDRA CALVINOfficer | 22K | $903K | 0.024% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | ROY BAYNESDirector | 33K | $1.4M | 0.036% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-13 | Christopher ClineOfficer | 65 | $2K | 0.000% | 2026-04-13 | Morgan Stanley Smith Barney |
| 2026-04-06 | ROY BAYNESDirector | 10K | $330K | 0.011% | 2026-04-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-01 | ELIZABETH REEDOfficer | 10K | $300K | 0.011% | 2026-04-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of TVTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is JANUS HENDERSON GROUP PLC at 11.9% of the class (10,599,660 shares), filed 2025-11-14 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Armistice Capital, LLCinvestment adviser, other entity | 1.6M | 1.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Steven Boydparent holding company, individual | 1.6M | 1.7% | 2026-06-30 |
| 2026-08-12 | 13G | BANK OF AMERICA CORP /DE/parent holding company | 5.4M | 5.8% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 4.3M | 4.6% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | FMR LLCparent holding company | 7.1M | 7.7% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 7.1M | 7.7% | 2026-06-30 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 4.7M | 5.1% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 9 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 1 | Joseph Edelmanindividual | 4.3M | 4.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Perceptive Advisors LLCinvestment adviser | 4.3M | 4.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Perceptive Life Sciences Master Fund, Ltd.corporation | 4.3M | 4.8% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Macquarie Group Limitedparent holding company | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Macquarie Management Holdings Incparent holding company | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Macquarie Investment Management Business Trustinvestment adviser | 0 | 0.0% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 2 | JANUS HENDERSON GROUP PLCinvestment adviser, parent holding company | 10.6M | 11.9% | 2025-09-30 |
13F holders
Tracked managers holding TVTX at their latest 13F. JSON8 of the 30 tracked managers held TVTX at their latest 13F, $325.4M in total at quarter-end prices. Renaissance Technologies is the largest at $104.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 1.8M | $104.1M | 0.14% | -134K |
| Two Sigma Investments | 2026-06-30 | 1.6M | $88.9M | 0.06% | +57K |
| D. E. Shaw & Co. | 2026-06-30 | 1.4M | $81.8M | 0.04% | +604K |
| Point72 Asset Management | 2026-06-30 | 479K | $27.2M | 0.03% | new |
| AQR Capital Management | 2026-06-30 | 270K | $15.3M | 0.01% | -35K |
| Millennium Management | 2026-06-30 | 85K | $4.8M | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 38K | $2.2M | 0.00% | -90K |
| Fisher Asset Management | 2026-06-30 | 16K | $900K | 0.00% | -18K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Travere Therapeutics reported revenue of $169.6M, up 48.2% from the same quarter a year earlier, and net loss of $34.8M (-0.37 diluted EPS). In FY 2025 it generated $37.8M of operating cash flow.
- Cash
- $117.7M
- Equity
- $24.5M
- Total assets
- $799.4M
- Shares outstanding
- 94,261,082
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $169.6M | -$34.8M | -20.5% | -0.37 |
| Q1 FY 2026 | 2026-03-31 | $127.2M | -$37.1M | -29.2% | -0.40 |
| Q4 FY 2025derived | 2025-12-31 | $129.7M | $2.7M | 2.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $164.9M | $25.7M | 15.6% | 0.28 |
| Q2 FY 2025 | 2025-06-30 | $114.4M | -$12.8M | -11.1% | -0.14 |
| Q1 FY 2025 | 2025-03-31 | $81.7M | -$41.2M | -50.4% | -0.47 |
| Q4 FY 2024derived | 2024-12-31 | $74.8M | -$60.3M | -80.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $62.9M | -$54.8M | -87.1% | -0.70 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $490.7M | -$25.5M | $37.8M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | $233.2M | -$321.5M | -$237.5M | n/a | n/a | n/a |
| FY 2023 | 2023-12-31 | $145.2M | -$111.4M | -$280.0M | $668K | n/a | n/a |
| FY 2022 | 2022-12-31 | $109.5M | -$278.5M | -$186.3M | $191K | n/a | n/a |
| FY 2021 | 2021-12-31 | $131.8M | -$180.1M | -$14.8M | $5.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
What this page is
Travere Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Travere Therapeutics (TVTX), SEC CIK 1438533, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-11-02.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1438533Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of TVTX is sold short?
10,913,583 shares were held short at the 2026-10-15 settlement, 5.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TVTX's daily short volume?
On 2026-11-02, 689,931 of the 1,210,190 TVTX shares reported to FINRA were sold short, 57.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TVTX have fails to deliver?
The SEC's latest file shows 144 TVTX shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are TVTX insiders buying or selling?
Insiders at TVTX reported 49 open-market sells worth $80.1M in the last 90 days and no open-market buys. Latest filing: Dube Eric M (CHIEF EXECUTIVE OFFICER) on 2026-10-15.
Have TVTX insiders filed to sell?
50 Form 144 notices on file for TVTX worth $95.5M at the prices reported; 16 in the last 90 days worth $81.0M. Latest: ERIC DUBE filed on 2026-10-15 to sell 243,735 shares ($13.0M) from 2026-10-15.
Who owns 5% or more of TVTX?
5 holders report 5% or more of TVTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is JANUS HENDERSON GROUP PLC at 11.9% of the class (10,599,660 shares), filed 2025-11-14 for an event on 2025-09-30.
What did TVTX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Travere Therapeutics reported revenue of $169.6M, up 48.2% from the same quarter a year earlier, and net loss of $34.8M (-0.37 diluted EPS). In FY 2025 it generated $37.8M of operating cash flow.
Which tracked 13F managers own TVTX?
8 of the 30 tracked 13F managers held TVTX shares at their latest filing, $325.4M in all. The largest: Renaissance Technologies (1.8M shares, $104.1M), Two Sigma Investments (1.6M shares, $88.9M), D. E. Shaw & Co. (1.4M shares, $81.8M), Steve Cohen's Point72 Asset Management (479K shares, $27.2M), Cliff Asness's AQR Capital Management (270K shares, $15.3M), Izzy Englander's Millennium Management (85K shares, $4.8M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.